L’Oréal is looking to buy all of the parent company of La Roche-Posay, submitting an offer to acquire the totality of the shares of Holding STRP (Société des Thermes de La Roche-Posay). The company said that the offer project foresees the prior carve out of the hotel business to the current shareholders of Holding STRP and the attribution of exclusive negotiation rights to L'Oréal.
“This acquisition project will enable us to sustain and reinforce the dermatologic position of La Roche-Posay by developing the existing indications and making the thermal station a flagship for the brand,” Laetitia Toupet, international general manager of La Roche-Posay, said.
Founded in 1921, the Société des Thermes de La Roche-Posay became the first thermal station in Europe exclusively dedicated to the treating of dermatological diseases. It is currently recommended by over 90,000 dermatologists worldwide, and in 2017 generated sales of more than €3.6 million, the company said.
The beauty brand's products are formulated with thermal water, and its key ingredients include lipikar for dry skin, anthélios for photoprotection, effaclar for acne, toléerane for sensitive skin and cicaplast for skin repair.
L’Oréal said its offer for the acquisition has been submitted for consultation to employee representatives and should be completed in the following months.